Key result
Fe3+/AMP hydrogel reduces fibrosis ~49% and improves LVEF in MI mice.
Why the study?
Existing injectable hydrogels for myocardial infarction rarely address oxidative stress, hypoxia, and dysregulated inflammation simultaneously, and excessive ROS scavenging may paradoxically cause oxidative damage.
Does an injectable Chito-oligosaccharide-hyaluronic acid hydrogel with Fe3+/AMP nano-enzyme improve cardiac regeneration and function in myocardial infarction mouse models?
Does an injectable Chito-oligosaccharide-hyaluronic acid hydrogel with Fe3+/AMP nano-enzyme improve cardiac regeneration and function in myocardial infarction mouse models?
A novel injectable hydrogel with Fe3+/AMP nano-enzyme significantly improved left ventricular ejection fraction and reduced fibrosis in a mouse model of myocardial infarction by modulating the post-infarction microenvironment.
INTRODUCTION: The post-infarction microenvironment, dominated by oxidative stress, hypoxia, and dysregulated inflammation, severely limits cardiac regeneration. Existing injectable hydrogels for myocardial infarction (MI) rarely address these factors simultaneously, and excessive reactive oxygen species (ROS) scavenging may paradoxically cause oxidative damage. OBJECTIVES: To develop an injectable hydrogel capable of concurrently scavenging ROS, sustaining oxygen release, and modulating immune responses without inducing oxidative damage. METHODS: /adenosine monophosphate (AMP) nano-enzyme for oxygen generation and redox stability. Carboxyl-modified chitosan oligosaccharide (C-COS) was designed to promote M2 macrophage polarization. The hydrogel was evaluated in vitro for oxidative stress protection and hypoxia tolerance, and in MI mouse models for oxygen retention, inflammation modulation, and cardiac repair. RESULTS: /AMP enhanced HUVEC survival by 28.9% under oxidative stress and accelerated scratch closure by 26.9% under hypoxia. In vivo, photoacoustic imaging confirmed prolonged oxygen retention; qRT-PCR revealed a 4.1-fold increase in TGF-β expression. After 28 days, MI mice showed 49% reduced fibrosis, 37% thicker ventricular walls, and improved left ventricular ejection fraction (58.3 ± 3.1%), all exceeding C-COS-OHA-CAT performance. CONCLUSION: /AMP hydrogel integrates ROS scavenging, oxygen modulation, and immunoregulation into a single injectable platform, representing a shift from single-mechanism MI hydrogels to comprehensive microenvironmental regulation for enhanced cardiac regeneration.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Myocardial infarction. Injectable Chito-oligosaccharide-hyaluronic acid hydrogels with Fe3+/AMP nano-enzyme vs. C-COS-OHA-CAT was evaluated on Cardiac repair (fibrosis, ventricular wall thickness, left ventricular ejection fraction). The Fe3+/AMP hydrogel reduced fibrosis by 49%, increased ventricular wall thickness by 37%, and improved left ventricular ejection fraction to 58.3% at 28 days in MI mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: